Injectable medications bypass this, but they can be uncomfortable and intimidating for many patients
2013, Jovanovic et al
Tirzepatide versus semaglutide once weekly in patients with Type 2 diabetes, The New England Journal of Medicine (2021) Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity, JAMA Network (2022) Tirzepatide once weekly for the treatment of obesity, The New England Journal of Medicine (2022) Mounjaro, tirzepatide injection, solution, DailyMed (2024) Ozempic semaglutide injection, solution, DailyMed (2023) Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial, Lancet (2021) FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, U.S
"STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (STEP 1)"
The Alarming: Mixed satisfaction rates nationwide, unpredictable side effects, and dangerous safety incidents that have prompted FDA crackdowns across multiple states
